283 related articles for article (PubMed ID: 26455787)
1. Which one performs better for targeted lung cancer combination therapy: pre- or post-bombesin-decorated nanostructured lipid carriers?
Du J; Li L
Drug Deliv; 2016 Jun; 23(5):1799-809. PubMed ID: 26455787
[TBL] [Abstract][Full Text] [Related]
2. Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA.
Shao Z; Shao J; Tan B; Guan S; Liu Z; Zhao Z; He F; Zhao J
Int J Nanomedicine; 2015; 10():1223-33. PubMed ID: 25709444
[TBL] [Abstract][Full Text] [Related]
3. Lung cancer combination therapy: co-delivery of paclitaxel and doxorubicin by nanostructured lipid carriers for synergistic effect.
Wang Y; Zhang H; Hao J; Li B; Li M; Xiuwen W
Drug Deliv; 2016 May; 23(4):1398-403. PubMed ID: 26079530
[TBL] [Abstract][Full Text] [Related]
4. Lung cancer gene therapy: Transferrin and hyaluronic acid dual ligand-decorated novel lipid carriers for targeted gene delivery.
Zhang B; Zhang Y; Yu D
Oncol Rep; 2017 Feb; 37(2):937-944. PubMed ID: 27959442
[TBL] [Abstract][Full Text] [Related]
5. Targeted delivery of doxorubicin into tumor cells by nanostructured lipid carriers conjugated to anti-EGFRvIII monoclonal antibody.
Abdolahpour S; Toliyat T; Omidfar K; Modjtahedi H; Wong AJ; Rasaee MJ; Kashanian S; Paknejad M
Artif Cells Nanomed Biotechnol; 2018 Feb; 46(1):89-94. PubMed ID: 28296511
[TBL] [Abstract][Full Text] [Related]
6. Transferrin-modified nanostructured lipid carriers as multifunctional nanomedicine for codelivery of DNA and doxorubicin.
Han Y; Zhang Y; Li D; Chen Y; Sun J; Kong F
Int J Nanomedicine; 2014; 9():4107-16. PubMed ID: 25187713
[TBL] [Abstract][Full Text] [Related]
7. Nanostructured lipid carriers as novel drug delivery system for lung cancer gene therapy.
Han Y; Li Y; Zhang P; Sun J; Li X; Sun X; Kong F
Pharm Dev Technol; 2016; 21(3):277-81. PubMed ID: 25560648
[TBL] [Abstract][Full Text] [Related]
8. Co-delivery of baicalein and doxorubicin by hyaluronic acid decorated nanostructured lipid carriers for breast cancer therapy.
Liu Q; Li J; Pu G; Zhang F; Liu H; Zhang Y
Drug Deliv; 2016 May; 23(4):1364-8. PubMed ID: 25874959
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer targeted chemotherapy based on doxorubicin-loaded bombesin peptide modified nanocarriers.
Wang C; Sun X; Wang K; Wang Y; Yang F; Wang H
Drug Deliv; 2016 Oct; 23(8):2697-2702. PubMed ID: 26203692
[TBL] [Abstract][Full Text] [Related]
10. Combined using of paclitaxel and salinomycin active targeting nanostructured lipid carriers against non-small cell lung cancer and cancer stem cells.
Zhou J; Sun M; Jin S; Fan L; Zhu W; Sui X; Cao L; Yang C; Han C
Drug Deliv; 2019 Dec; 26(1):281-289. PubMed ID: 30880491
[TBL] [Abstract][Full Text] [Related]
11. Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells.
Zhang XG; Miao J; Dai YQ; Du YZ; Yuan H; Hu FQ
Int J Pharm; 2008 Sep; 361(1-2):239-44. PubMed ID: 18586075
[TBL] [Abstract][Full Text] [Related]
12. Preparation and characteristics of nanostructured lipid carriers for control-releasing progesterone by melt-emulsification.
Yuan H; Wang LL; Du YZ; You J; Hu FQ; Zeng S
Colloids Surf B Biointerfaces; 2007 Nov; 60(2):174-9. PubMed ID: 17656075
[TBL] [Abstract][Full Text] [Related]
13. Engineering of lipid prodrug-based, hyaluronic acid-decorated nanostructured lipid carriers platform for 5-fluorouracil and cisplatin combination gastric cancer therapy.
Qu CY; Zhou M; Chen YW; Chen MM; Shen F; Xu LM
Int J Nanomedicine; 2015; 10():3911-20. PubMed ID: 26089667
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin-loaded nanocarriers: A comparative study of liposome and nanostructured lipid carrier as alternatives for cancer therapy.
Fernandes RS; Silva JO; Monteiro LOF; Leite EA; Cassali GD; Rubello D; Cardoso VN; Ferreira LAM; Oliveira MC; de Barros ALB
Biomed Pharmacother; 2016 Dec; 84():252-257. PubMed ID: 27664949
[TBL] [Abstract][Full Text] [Related]
15. Sclareol is a potent enhancer of doxorubicin: Evaluation of the free combination and co-loaded nanostructured lipid carriers against breast cancer.
Borges GSM; Silva JO; Fernandes RS; de Souza ÂM; Cassali GD; Yoshida MI; Leite EA; de Barros ALB; Ferreira LAM
Life Sci; 2019 Sep; 232():116678. PubMed ID: 31344429
[TBL] [Abstract][Full Text] [Related]
16. Curcumin-guided nanotherapy: a lipid-based nanomedicine for targeted drug delivery in breast cancer therapy.
Lin M; Teng L; Wang Y; Zhang J; Sun X
Drug Deliv; 2016 May; 23(4):1420-5. PubMed ID: 26203688
[TBL] [Abstract][Full Text] [Related]
17. Co-delivery of plasmid DNA and doxorubicin by solid lipid nanoparticles for lung cancer therapy.
Han Y; Zhang P; Chen Y; Sun J; Kong F
Int J Mol Med; 2014 Jul; 34(1):191-6. PubMed ID: 24804644
[TBL] [Abstract][Full Text] [Related]
18. Co-delivery of doxorubicin, docosahexaenoic acid, and α-tocopherol succinate by nanostructured lipid carriers has a synergistic effect to enhance antitumor activity and reduce toxicity.
Lages EB; Fernandes RS; Silva JO; de Souza ÂM; Cassali GD; de Barros ALB; Miranda Ferreira LA
Biomed Pharmacother; 2020 Dec; 132():110876. PubMed ID: 33113428
[TBL] [Abstract][Full Text] [Related]
19. The anti-tumor and renoprotection study of E-[c(RGDfK)
Zhang B; Zhang Y; Dang W; Xing B; Yu C; Guo P; Pi J; Deng X; Qi D; Liu Z
J Nanobiotechnology; 2022 Sep; 20(1):425. PubMed ID: 36153589
[TBL] [Abstract][Full Text] [Related]
20. Development, characterization and evaluation of doxorubicin nanostructured lipid carriers for prostate cancer.
Zhang HW; Dang Q; Zhang ZW; Wu FS
J BUON; 2017; 22(1):102-111. PubMed ID: 28365942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]